Thermo Fisher Scientific (NYSE:TMO) Shares Gap Down – Here’s Why

Thermo Fisher Scientific Inc. (NYSE:TMO) shares gapped down prior to trading on Wednesday. The stock had previously closed at $687.37, but opened at $665.00. Thermo Fisher Scientific shares last traded at $690.1890, with a volume of 732,999 shares changing hands.

Key Stories Impacting Thermo Fisher Scientific

Here are the key news stories impacting Thermo Fisher Scientific this week:

• Positive Sentiment: Q3 results exceeded expectations. Revenue increased 9% year over year to $12.14 billion, while adjusted EPS rose 15% to $6.68, surpassing the $6.40 consensus estimate. Organic growth reached 6%, supported by laboratory products and services, clinical research, bioproduction and improving end-market demand. Thermo Fisher Scientific Reports Third Quarter 2026 Results
• Positive Sentiment: Management raised its full-year outlook. Thermo Fisher lifted its 2026 organic revenue-growth expectation to 4% and increased full-year earnings and revenue guidance, indicating continued customer activity and improving demand. Operating margin expansion also contributed to profit growth. Thermo Fisher Scientific: 3 Key Takeaways for Long-Term Investors
• Positive Sentiment: Analysts became more bullish. TD Cowen raised its price target to $810 and Stifel Nicolaus to $775, both with buy ratings; Robert W. Baird raised its target to $756 and maintained an outperform rating. TD Cowen price target
• Neutral Sentiment: Industry trends remain favorable. Research forecasts point to expanding peptide-synthesis and bioprocessing markets, including demand linked to GLP-1 drugs and biologics manufacturing. These opportunities benefit Thermo Fisher’s addressable markets but do not represent company-specific bookings or guidance.
• Negative Sentiment: The stock’s reaction has been cautious despite the beat. With shares near their 52-week high and trading at a premium earnings multiple, investors may have expected an even larger outlook increase. Unusual put-option activity also signals near-term hedging or bearish positioning.

Analysts Set New Price Targets

A number of analysts have issued reports on the stock. UBS Group reiterated a “buy” rating and issued a $800.00 target price on shares of Thermo Fisher Scientific in a research note on Thursday. Wall Street Zen upgraded Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research note on Saturday, October 3rd. Evercore set a $570.00 target price on shares of Thermo Fisher Scientific in a research note on Monday, July 6th. HSBC upgraded Thermo Fisher Scientific from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, September 1st. Finally, Sanford C. Bernstein started coverage on shares of Thermo Fisher Scientific in a research report on Friday, June 26th. They set a “market perform” rating and a $520.00 target price on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, three have assigned a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $675.52.

Thermo Fisher Scientific Stock Down 2.6%

The company has a current ratio of 1.81, a quick ratio of 1.18 and a debt-to-equity ratio of 0.71. The company has a market cap of $249.98 billion, a price-to-earnings ratio of 36.37, a price-to-earnings-growth ratio of 2.89 and a beta of 0.87. The firm’s fifty day moving average price is $644.01 and its 200-day moving average price is $553.96.

Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Wednesday, October 21st. The medical research company reported $6.68 EPS for the quarter, topping the consensus estimate of $6.40 by $0.28. The firm had revenue of $12.14 billion for the quarter, compared to the consensus estimate of $11.95 billion. Thermo Fisher Scientific had a net margin of 14.94% and a return on equity of 17.33%. The business’s quarterly revenue was up 9.1% on a year-over-year basis. During the same period last year, the company posted $5.79 EPS. Sell-side analysts predict that Thermo Fisher Scientific Inc. will post 25.16 earnings per share for the current year.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction on Thursday, August 20th. The stock was sold at an average price of $629.27, for a total transaction of $6,292,700.00. Following the completion of the sale, the chief executive officer owned 123,925 shares of the company’s stock, valued at $77,982,284.75. This trade represents a 7.47% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael D. Shafer sold 25,500 shares of the business’s stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $600.00, for a total value of $15,300,000.00. Following the sale, the executive vice president owned 20,994 shares of the company’s stock, valued at approximately $12,596,400. This represents a 54.85% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 73,768 shares of company stock valued at $44,122,820 in the last 90 days. Company insiders own 0.33% of the company’s stock.

Hedge Funds Weigh In On Thermo Fisher Scientific

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. BlackRock Inc. acquired a new stake in Thermo Fisher Scientific in the second quarter valued at about $15,501,867,000. Bank of New York Mellon Corp acquired a new position in Thermo Fisher Scientific during the second quarter worth about $1,974,561,000. Bank of America Corp DE acquired a new position in Thermo Fisher Scientific during the second quarter worth about $1,952,930,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in shares of Thermo Fisher Scientific by 0.9% in the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 2,472,524 shares of the medical research company’s stock worth $1,239,625,000 after acquiring an additional 22,827 shares during the last quarter. Finally, Legal & General Group Plc bought a new position in shares of Thermo Fisher Scientific in the second quarter worth about $1,122,351,000. 89.23% of the stock is owned by institutional investors and hedge funds.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc is a global supplier of laboratory products, analytical instruments, reagents, consumables, software and services used in scientific research, healthcare, pharmaceuticals, biotechnology and industrial applications. The company serves customers ranging from academic institutions and government agencies to hospitals, clinical laboratories and pharmaceutical manufacturers.

Its offerings include instruments and systems for genetic analysis, mass spectrometry, chromatography, electron microscopy and materials science, as well as molecular biology reagents, cell culture products, laboratory plastics and research chemicals.